肺癌筛查超越吸烟资格标准:证据、局限与中国的经验
本综述基于两项充分把握度的随机对照试验,指出低剂量CT筛查可降低高累积烟草暴露人群的肺癌死亡率,但能否外推至不同风险特征人群(尤其中国大量无显著吸烟史肺癌患者)尚未解决。作者提出三个论点:分期迁移与风险富集必要但不充分,晚期发病率下降是更可靠获益信号;基于吸烟暴露队列的风险预测模型在无显著吸烟史人群中可靠性最差;证据充分性应视为连续谱而非二元。中国项目显示LDCT可广泛实施并富集早期检出,但未能确立可接受危害下的肺癌死亡率下降,且近期中国和韩国数据提示向平均风险人群扩散可能扩大过度诊断。
要点
- LDCT降低肺癌死亡率的结论仅基于高累积烟草暴露人群的两项RCT。
- 晚期发病率下降比分期迁移更可靠地反映筛查获益。
- 无显著吸烟史人群的资格决策应基于晚期发病率下降的前瞻证据。
核心结论
- LDCT筛查降低肺癌死亡率的证据仅适用于高累积烟草暴露人群。
- 无显著吸烟史人群的筛查获益尚未解决,资格扩展应基于晚期发病率下降的前瞻证据。
- 分期迁移易受领先时间偏倚、长度偏倚和过度诊断影响,不能单独作为获益信号。
研究设计与样本
- 本文为综述,未系统检索全部文献,而是围绕三个论点展开论述。
- 结论基于两项在烟草暴露人群中开展的充分把握度随机对照试验。
主要发现
- LDCT可在人群中广泛实施并富集早期检出,但未能确立可接受危害下的肺癌死亡率下降。
- 基于烟草暴露队列的风险预测模型在无显著吸烟史人群中可靠性最差。
- 近期中国和韩国数据提示LDCT向平均风险人群扩散可能扩大过度诊断而非净获益。
关键数值与推荐
- 证据充分性应视为连续谱,而非随机试验与无证据的二元判断。
临床怎么用
- 无显著吸烟史人群的筛查资格决策应依据晚期发病率下降的前瞻证据,而非仅分期迁移富集。
- 筛查扩展应在严格的前瞻性评估框架内进行。
局限性
- 本文为论述性综述,未系统检索全部文献。
- 无显著吸烟史人群的筛查获益缺乏充分随机对照试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low-dose computed tomography (LDCT) screening lowers lung cancer mortality in populations with substantial cumulative tobacco exposure, and that conclusion rests on two adequately powered randomized controlled trials. Whether the same benefit extends to populations with different risk profiles remains unresolved, particularly in China, where a substantial share of lung cancers arise in individuals without substantial smoking history. This review develops three linked arguments rather than surveying the field exhaustively. First, stage shift and risk-enrichment are necessary but not sufficient; a concurrent reduction in advanced-stage incidence is the more reliable signal of benefit. Second, risk-prediction models built on tobacco-exposed cohorts are least dependable in individuals without substantial smoking history, precisely where expanding eligibility relies on them most. Third, judging evidentiary sufficiency requires an explicit framework that treats sufficiency as a continuum rather than a binary between a randomized trial and nothing. Chinese programs illustrate all three at scale: LDCT can be delivered broadly and can enrich early-stage detection, yet still not establish reduced lung cancer mortality with acceptable harm. Stage-shift findings remain vulnerable to lead-time bias, length bias, and overdiagnosis, and recent data from China and South Korea suggest that diffusion of LDCT into populations at average risk may enlarge overdiagnosis more than net benefit. For populations without substantial smoking history, eligibility decisions should rest on prospective evidence of reduced advanced-stage incidence rather than stage-shift enrichment alone; expansion belongs within disciplined prospective evaluation.
引用
- He F, Xu Y, Tu B, et al. Lung Cancer Screening Beyond Smoking-Based Eligibility: Evidence, Limits, and Lessons From China. Chest. 2026. PMID: 42833546. doi:10.1016/j.chest.2026.09.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。